An update from Anagenics Limited ( (AU:AN1) ) is now available.
Roquefort Therapeutics has signed a binding share purchase agreement to sell its wholly-owned subsidiary Lyramid Pty Ltd to Pleiades Pharma Limited for US$10.8 million, comprising equity and potential upfront cash. This transaction allows Roquefort to hold a significant equity position in Pleiades, a well-funded company with a robust portfolio of clinical and pre-clinical assets. The sale is contingent upon Pleiades completing fundraising and certain in-licensing transactions by June 30, 2025. Anagenics Limited has acknowledged this transaction but has no additional details beyond what has been announced.
More about Anagenics Limited
Anagenics Limited is a health, beauty, and wellness business focused on increasing shareholder value through the global distribution and sales of its proprietary and licensed brands of clinically validated anti-aging solutions. Its subsidiary, BLC Cosmetics Pty Ltd, concentrates on the sales and distribution of leading Australian and international cosmetic and wellness products.
Current Market Cap: A$3.69M
See more data about AN1 stock on TipRanks’ Stock Analysis page.